Seres Therapeutics Company Profile (NASDAQ:MCRB)

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Seres Therapeutics Inc (NASDAQ:MCRB) released its quarterly earnings data on Thursday, May, 4th. The company reported ($0.63) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.02. The business had revenue of $3.02 million for the quarter, compared to analysts' expectations of $3 million. Seres Therapeutics had a negative net margin of 844.91% and a negative return on equity of 83.72%. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.50) EPS. View Seres Therapeutics' Earnings History.

Seres Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 9th 2017. View Earnings Estimates for Seres Therapeutics.

7 equities research analysts have issued 12-month target prices for Seres Therapeutics' stock. Their forecasts range from $12.00 to $50.00. On average, they expect Seres Therapeutics' share price to reach $23.20 in the next year. View Analyst Ratings for Seres Therapeutics.

Here are some recent quotes from research analysts about Seres Therapeutics stock:

• 1. Cowen and Company analysts commented, "We are optimistic that modifications to the clinical trial plan for SER-109 in recurrent." (5/19/2017)
• 2. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (2/2/2017)
• 3. Canaccord Genuity analysts commented, "We believe that SER-109 Phase 2 trial study power was decreased by the inclusion of misdiagnosed and non-disease active patients. MCRB indicated that 72 of the 89 patients enrolled in the Phase 2 trials were chosen based on C. Difficile PCR diagnosis. A positive PCR test indicates that the cytotoxin gene is present, but does not directly indicate that the C. Difficile bacterium is producing the cytotoxin that causes the underlying symptoms. Thus a direct testing of cytotoxin is the most indicative of disease activity, and further qualifying stool samples analysis showed that only 15 of 31 PCR- positive samples were cytotoxin-positive. Importantly, Optimer utilized toxin testing for its fidaxomicin clinical program for recurrent C." (1/31/2017)

Some companies that are related to Seres Therapeutics include Insys Therapeutics (INSY), Alder BioPharmaceuticals (ALDR), Amarin Corporation PLC (AMRN), Acorda Therapeutics (ACOR), Five Prime Therapeutics (FPRX), Ascendis Pharma A/S (ASND), Epizyme (EPZM), ZIOPHARM Oncology (ZIOP), Coherus BioSciences (CHRS), Revance Therapeutics (RVNC), Achaogen (AKAO), NeuroDerm (NDRM), Aduro Biotech (ADRO), Keryx Biopharmaceuticals (KERX), Retrophin (RTRX), Aclaris Therapeutics (ACRS), Vanda Pharmaceuticals (VNDA) and REGENXBIO (RGNX).

Seres Therapeutics' management team includes the folowing people:

• Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer
• Eric D. Shaff, Chief Financial Officer, Executive Vice President
• John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing
• David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development
• Thomas J. DesRosier J.D., Chief Legal Officer, Executive Vice President and Secretary
• Wael Hashad, Chief Commercial Officer, Executive Vice President
• Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President
• Noubar B. Afeyan Ph.D., Lead Independent Director
• Dennis A. Ausiello M.D., Independent Director
• Gregory Behar, Independent Director

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Flagship Pioneering Inc. (31.42%), FMR LLC (14.99%), Vanguard Group Inc. (3.88%), JPMorgan Chase & Co. (0.92%), Renaissance Technologies LLC (0.87%) and Wellington Management Group LLP (0.46%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship. View Institutional Ownership Trends for Seres Therapeutics.

Seres Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Renaissance Technologies LLC, Morgan Stanley, Oxford Asset Management, Wellington Management Group LLP, ProShare Advisors LLC, Teachers Advisors LLC and TD Asset Management Inc.. Company insiders that have sold Seres Therapeutics stock in the last year include Eric D Shaff, John G Aunins, Michele Trucksis and Roger Pomerantz. View Insider Buying and Selling for Seres Therapeutics.

Seres Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Spark Investment Management LLC, JPMorgan Chase & Co., American Century Companies Inc., Tudor Investment Corp ET AL, Dimensional Fund Advisors LP, Highbridge Capital Management LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Seres Therapeutics.

Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Seres Therapeutics stock can currently be purchased for approximately $12.10.